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Abstract
Background: Pancreatic ductal adenocarcinoma is a lethal disease with a 5-year survival rate of 4% and typically
presents in an advanced stage. In this setting, prognostic markers identifying the more agrressive tumors could aid
in managment decisions. Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3, also known as IMP3 or
KOC) is an oncofetal RNA-binding protein that regulates targets such as insulin-like growth factor-2 (IGF-2) and
ACTB (beta-actin).
Methods: We evaluated the expression of IGF2BP3 by immunohistochemistry using a tissue microarray of 127
pancreatic ductal adenocarcinomas with tumor grade 1, 2 and 3 according to WHO criteria, and the prognostic
value of IGF2BP3 expression.
Results: IGF2BP3 was found to be selectively overexpressed in pancreatic ductal adenocarcinoma tissues but not
in benign pancreatic tissues. Nine (38%) patient samples of tumor grade 1 (n = 24) and 27 (44%) of tumor grade 2
(n = 61) showed expression of IGF2BP3. The highest rate of expression was seen in poorly differentiated specimen
(grade 3, n = 42) with 26 (62%) positive samples. Overall survival was found to be significantly shorter in patients
with IGF2BP3 expressing tumors (P = 0.024; RR 2.3, 95% CI 1.2-4.8).
Conclusions: Our data suggest that IGF2BP3 overexpression identifies a subset of pancreatic ductal
adenocarcinomas with an extremely poor outcome and supports the rationale for developing therapies to target
the IGF pathway in this cancer.
Background
Pancreatic ductal adenocarcinoma is a lethal neoplasm
with a 5-year survival rate of 4%. Patients typically pre-
sent with advanced disease. Prognostic markers that
identify the more aggressive tumors could aid in man-
agement and treatment decisions. The insulin-like
growth factor-2 mRNA binding protein family com-
prises three proteins, IGF2BP1-3, that regulate mRNA
transport, translation, and turnover by binding to the
coding regions of target mRNAs such as IGF-2 (insulin-
like growth factor 2), c-myc, and beta-actin [1-4].
IGF2BP3 was first cloned from a pancreatic tumor
cDNA screen and was originally designated as KOC
(KH-domain containing protein overexpressed in can-
cer) [5]. It is known as an oncofetal protein because its
expression is highest during embryogenesis [6-10], and
is completely silenced in normal adult mouse tissues
and is almost so in normal adult human tissues (with
fibroblasts, lymphocytes, and the testes being the excep-
tions) [10,11]. In a previous study, Mueller-Pillasch et al.
provided evidence to suggest that IGF2BP3 may play a
role in the differentiation of the human exocrine pan-
creas during embryogenesis [12]. Although the function
of IGF2BP3 in pancreatic ductal adenocarcinoma
remains unclear, transgenic overexpression of the
* Correspondence: david.schaeffer@web.de
1Department of Pathology, The University of British Columbia, Vancouver BC,
Canada
Schaeffer et al. BMC Cancer 2010, 10:59
http://www.biomedcentral.com/1471-2407/10/59
© 2010 Schaeffer et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
protein in mice was reported to induce abnormalities in
the exocrine pancreas [13]. In addition, recent reports
have demonstrated high levels of IGF2BP3 mRNA tran-
script and protein in pancreatic cancer tissues but not
in benign lesions of the pancreas, chronic pancreatitis
and/or normal pancreatic tissues [14,15]. The expression
of IGF2BP3 has also been associated with an unfavor-
able outcome in renal clear cell carcinoma [16,17] and
more recently, in ovarian clear cell carcinoma [18].
Collectively, these observations led us to postulate that
IGF2BP3 expression could be a prognostic indicator for
pancreatic ductal adenocarcinoma. The objective of the
present study was to determine if expression of
IGF2BP3 correlates with patient prognosis.
Methods
Patients and tumor specimens
The expression of IGF2BP3 and IGF-2 was evaluated by
immunohistochemistry on a tissue microarray of 127
pancreatic adenocarcinoma, ranging from tumor grade
1, 2 and 3, (according to WHO criteria [19]), from
patients who underwent surgical resection at Vancouver
General Hospital. A retrospective analysis of the avail-
able clinical data was performed. Ethics approval was
obtained from the University of British Columbia Ethics
Review Board. Age, gender, concomitant illnesses, pre-
vious surgeries, and survival data, was collected via a
retrospective chart review of the patients referred to the
British Columbia Cancer Agency and transferred to an
anonymized database. Pathological staging and histologi-
cal tumor grade were determined from the original
hematoxylin and eosin stained slides. According to the
AJCC (6th edition) classification, the study cohort was
distributed as follows: IA (n = 1), IB (n = 34), IIA (n =
19), IIB (n = 65), III (n = 6) and IV (n = 2). Resection
status was determined as follows: R0 (n = 82), R1 (n =
37) and R2 (n = 8). Clinical and morphological data are
summarized in Table 1.
A tissue microarray (TMA) was constructed using
duplicate 0.6-mm cores generated from representative
areas of formalin-fixed, paraffin-embedded surgical exci-
sion blocks that had been reviewed by at least two
pathologists with appropriate subspecialty expertise.
Non-neoplastic pancreatic parenchyma (n = 14) served
as control tissue.
Treatment and outcome
The majority of patients with ductal adenocarcinoma
received surgical treatment with curative intent and did
not receive adjuvant chemotherapy. If given, adjuvant
chemotherapy was heterogeneous and included either
5FU alone, gemcitabine, or a combination of 5FU with
cisplatin. At the time of data collection, generalized pro-
vince wide treatment guidelines for this particular neo-
plasm were still in development. The study endpoint
was defined as disease specific survival. This information
was available for 127 patients. Mean follow-up time was
13 ± 4.8 months (Table 1).
Immunohistochemical staining and scoring
Four-micron sections from the arrays were stained with
hematoxylin and eosin to confirm the presence of repre-
sentative tumor in each core. Sections were stained
using a mouse monoclonal antibody against IGF2BP3
(clone 69.1, 1:100 dilution, DAKO, Carpenteria, CA)
[20] and an anti-IGF-2 rabbit polyclonal antibody (1:100
dilution, Abcam, Cambridge, MA) raised against a
recombinant human IGF-2 protein. This specific IGF-2
antibody recognizes both the prohormone form of
IGF-2 (also named ‘big IGF-2, 15 kDa’) and the smaller
IGF-2 (7.5 kDa). Immunostaining was performed on a
Ventana Discovery XT (Ventana, Tucson, AZ) using a
standard CC1 heat-induced epitope retrieval protocol
(Ventana, Tucson, AZ), and DABMap detection system
(Ventana, Tucson, AZ). A cervical carcinoma was used
as a positive control with every staining run, and normal
pancreatic tissue, which was non-immunoreactive, was
used as a negative control. To aid the analysis of the
numerous tissue cores stained by immunohistochemis-
try, digital images were collected using a BLISS instru-
ment (Bacus Laboratories, Lombard, IL). Tissue cores
were scored on the basis of thepercentage of positive
tumor cells staining above background intensity in a
membranous and/or cytoplasmic pattern according to
published methodology [21]. In tumor cells, the staining
intensity was designated as either non-existent (0), weak
Table 1 Clinicopathological characteristics by tumor grade
N Gender Age Follow-up Treatment
Cohort by Grade M F Mean ± SD [month] Adjuvant Chemotherapy
WHO 1 24 18 6 60.8 ± 11.5 19 ± 3.6 6 (25%)
WHO 2 62 44 18 57.4 ± 12.3 13 ± 6.1 16 (26%)
WHO 3 42 30 12 54.3 ± 14.2 7 ± 4.8 28 (66%)
Sum/Mean 128 92 36 57.5 ± 12.6 13 ± 4.8 50 (39%)
SD - standard deviation
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(1), moderate (2) or strong (3). The number of cells was
scored as either no cells stained (0), <10% (1), 10-50%
(2), 50-80% (3) or > 80% (4). The final score was calcu-
lated by multiplying these two variables. A score of 0-5
was considered negative (IGF2BP3 and IGF-2 not over-
expressed), and a score of 6 and higher was considered
positive (overexpression of IGF2BP3 and IGF-2) in
accordance with Koebel et al. [21]. Discrepant score
results for duplicate cores, when present, were consoli-
dated as the higher interpretable score [22]. Cut-off
point for positive cases was any convincing cytoplasmic
expression in more than 5% of tumor cells. IGF2BP3
and IGF-2 staining on the tissue microarray was scored
by two pathologists (DFS and DRO) blinded to clinical
outcome. Discordant results were reviewed by a senior
pathologist (DAO) and consensus was reached.
Statistical Analysis
SPSS for Windows (Chicago, IL, USA; Version 14.0) was
used for statistical analyses. Survival curves were plotted
using the Kaplan-Meier method, with significance assessed
using log-rank tests. Cox proportional hazard model was
applied to perform multivariate analysis to determine the
independent effects of IGF2BP3 expression, age, AJCC
stage group, lymphovascular invasion, histological grade
and perineural invasion. Statistical significance was
declared if the P-value was < 0.05.
Results
IGF2BP3 expression pattern and survival
IGF2BP3 is selectively overexpressed in pancreatic duc-
tal adenocarcinoma tissues but not in benign pancreatic
tissues, consistent with previous reports [14,15]. In our
cohort, 63% of ductal adenocarcinoma showed IGF2BP3
expression (Figure 1). IGF2BP3 expression differed
between tumor grade (P < 0.001, Pearson’s Chi-square).
The highest rate of expression was seen in poorly differ-
entiated specimens (grade 3, n = 42) with 26 (62%) posi-
tive samples, followed by grade 2 (44%, n = 27), and
with the lowest rate of expression in tumour grade 1
samples (38%, n = 9). Figure 2 shows representative
H&E and IGF2BP3 staining of the tissue microarray.
The staining was readily appreciable in the tumor cells
as shown in a higher magnification photomicrograph
(Figure 3a). While IGF2BP3 expression was also
observed in premalignant pancreatic intraepithelial neo-
plasia (PanIN) lesions, mainly PanIN-3, this staining did
not show evidence of a grade dependent expression.
Disease specific survival for all tumor grades was
found to be significantly shorter in patients with
IGF2BP3 expressing tumors than in those with IGF2BP3
non-expressing tumors (9.3 months vs. 13.7 months,
respectively, P = 0.024, Figure 4). For IGF2BP3 expres-
sion, a risk ratio of 2.3 (95% CI 1.2-4.8), independent of
grade, was calculated and when stratified by treatment
subgroup, IGF2BP3 expression showed the same trend
for unfavorable prognosis.
To determine and compare the individual risk of
IGF2BP3 expression, age, AJCC stage group, lymphovas-
cular invasion, histological grade and perineural inva-
sion, a Cox proportional hazard analysis was performed
(Table 2). IGF2BP3 was found to be a significant inde-
pendent predictor of risk for the overall survival by
increasing the risk of death (HR 3.34 ± 1.93; P = 0.05).
However, no statistical significant difference was found
in comparing IGF2BP3 expression versus lack of expres-
sion in regard of resection status or administration of
chemotherapy.
IGF-2 expression pattern and its correlation with IGF2BP3
expression
Since the most studied IGF2BP3-regulated mRNA tran-
script is IGF-2, we examined the protein expression of
IGF-2 in relation to that of IGF2BP3. IGF-2, in compari-
son to IGF2BP3, was expressed not only in pancreatic
ductal adenocarcinoma, but also in benign pancreatic
tissue (Figure 2). However, the staining within benign
tissue was exclusively located in acinar cells and, like
IGF2BP3, absent in ductal cells, implying IGF2BP3-inde-
pendent regulation of IGF-2 expression in the acinar
cells. If present, the intensity of IGF-2 positive staining
was almost 2-fold higher than that of IGF2BP3 and
readily observable (Figure 2 and Figure 3b, c). While the
expression of IGF-2 was slightly different between
tumor grades, this was not statistical significant (P =
0.093; Figure 1). The expression of IGF2BP3 was signifi-
cantly and positively correlated with that of IGF-2 in
tumor cells (P = 0.02). Calculations for disease specific
survival for IGF-2 expression alone did not show any
difference between the cohorts (data not shown).
Discussion and Conclusions
Although IGF2BP3 is expressed in a variety of malig-
nant neoplasms including pulmonary small cell [23],
endometrial [20], and cervical carcinomas [24], the
prognostic value has been demonstrated only in renal
clear cell carcinomas [16,17], low-stage urothelial car-
cinomas of the bladder [25], and more recently in
ovarian clear cell carcinoma [18]. The present study
showed for the first time that IGF2BP3 overexpression
correlates with poor survival in pancreatic ductal ade-
nocarcinoma. We also demonstrated that the expres-
sion of IGF-2 significantly correlates with that of
IGF2BP3, which has been previously reported to pro-
mote IGF-2 mRNA translation [2]. An attractive fea-
ture of IGF2BP3 as a biomarker in pancreatic ductal
adenocarcinoma is that its expression is only found in
tumor tissue and is absent in normal adult pancreatic
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ductal tissue. This on-off pattern of expression makes
staining interpretation very simple in practice. The
expression of IGF2BP3 during embryogenesis [12] but
not in adulthood suggests that IGF2BP3 is epigeneti-
cally silenced in adult tissues. In pancreatic ductal
adenocarcinoma, re-expression of IGF2BP3 might
be the result of promoter hypomethylation. The
IGF2BP3 gene is located on chromosome 7p (at loca-
tion 23,316,354-23,476,520), a region not subject to
frequent perturbation in pancreatic ductal adenocarci-
noma [26]. It is therefore unlikely that gene amplifica-
tion is responsible for the observed IGF2BP3
expression in pancreatic ductal adenocarcinoma. We
are currently testing the hypothesis that the IGF2BP3
promoter is hypomethylated in pancreatic ductal ade-
nocarcinoma, and that this correlates with expression
levels. If this hypothesis holds true, IGF2BP3 could be
regarded as a target for re-methylating enzymes.
Figure 1 Expression of IGF2BP3 and IGF-2 staining. Bar graphs showing the percentages of low and high level positive (overexpression)
staining for IGF2BP3 and IGF-2 of grade 1, 2, and 3 pancreatic ductal adenocarcinomata, compared to benign ductal pancreatic tissues. Data
was obtained from 127 pancreatic ductal adenocarcinoma cases and 14 benign cases.
Schaeffer et al. BMC Cancer 2010, 10:59
http://www.biomedcentral.com/1471-2407/10/59
Page 4 of 8
Figure 2 Immunohistochemical staining for IGF2BP3 and IGF-2 by tumor grade. Representative tissue microarray cores of pancreatic ductal
adenocarcinomata with immunohistochemical staining for IGF2BP3 and IGF-2 by tumor grade. Note the complete lack of immunohistochemical
staining for IGF2BP3 in benign pancreatic tissue. While there appears to be positive staining for IGF-2 in the benign cores, this was exclusively
acinar staining and not ductal. [Scale bar, 100 μm.]
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The mechanisms by which IGF2BP3 and IGF-2
facilitate tumor progression in pancreatic ductal adeno-
carcinoma remain to be elucidated. However, IGF2BP3-
mediated activation of IGF-2 translation has been
shown to increase human leukemia cell proliferation [2].
Vikesaa et al. [27] reported that IGF2BP3 modulates the
expression of specific extracellular matrix and cell adhe-
sion proteins (e.g., collagen V a1, ALCAM) and stabi-
lizes CD44 mRNA, thereby promoting invadopodia
formation in cervical cancer cells. Moreover, IGF2BP3
has been demonstrated to enhance the motility of
human colorectal cancer cells [28]. While less studied
than its family member IGF-1, IGF-2 is also known to
play a role in cancer progression. Corcoran et al. [29]
recently noted that induction of IGF-2 expression in
pre-malignant lesions coincides with progression to
advanced medulloblastoma. In addition to its direct
effect on tumor cells, IGF-2 was shown to promote
tumor angiogenesis and lymphangiogenesis [30,31].
Decreases in IGF-2 mRNA levels and IGF-2 secretion
using growth hormone-releasing hormone antagonists
were associated with decreased cancer cell proliferation
in vitro [32] and tumor growth in vivo [33,34]. Further-
more, IGF-2 deficient tumor cells were shown to be
more sensitive to chemotherapy-induced apoptosis [35].
It seems reasonable to speculate that the IGF2BP3/IGF-
2 pathway may drive progression in pancreatic ductal
adenocarcinoma by similar means, and that therapeuti-
cally targeting either or both of these proteins may
result in tumor control. These possibilities are being
investigated in our laboratory. Interestingly, Wang et al.
Figure 4 Disease specific Survival Analysis. Kaplan-Meier analysis of disease specific survival in pancreatic ductal adenocarcinoma expressing
IGF2BP3 (black line, n = 62) and not expressing IGF2BP3 (grey line, n = 65). P value was calculated using the log-rank test.
Figure 3 Evaluation of staining intensity and number of stained
cells. IGF2BP3 (a) and IGF-2 (b) with strong and moderate staining
intensity in more than 80% of pancreatic ductal adenocarcinoma
cells, given a score of 12 and 8, respectively. In comparison weak
staining of IGF2BP3 (c) in less than 10% of cells in an example of a
grade 1 tumor, given a score of 1. [Scale bar, 200 μm.]
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reported that IGF2BP3 is immunogenic in lung cancer
patients, suggesting that it may be a potential target for
immunotherapy [36]. In a recent Phase I trial, IGF2BP3
vaccine was shown to be safe and well tolerated [37].
In summary, this is a retrospective study of a post-sur-
gical, heterogeneously treated cohort of patients with
resected pancreatic adenocarcinoma. Thus, prognostic
associations, defined as tumor behavior after primary
surgery and uninfluenced by different regimens of adju-
vant therapy, cannot be assessed. A strength of this
study is the relatively large sample size (n = 127) of pan-
creatic ductal adenocarcinoma. Our data suggest that
IGF2BP3 overexpression denotes a subset of pancreatic
adenocarcinomas with an extremely poor outcome, and
supports the rationale for developing therapies to target
the IGF2BP3/IGF-2 pathway in pancreatic ductal
adenocarcinoma.
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